{"id":21182,"date":"2025-01-10T22:23:03","date_gmt":"2025-01-10T14:23:03","guid":{"rendered":"https:\/\/flcube.com\/?p=21182"},"modified":"2025-01-10T22:23:07","modified_gmt":"2025-01-10T14:23:07","slug":"alchemab-therapeutics-partners-with-eli-lilly-to-discover-als-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21182","title":{"rendered":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments"},"content":{"rendered":"\n

UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY<\/a>) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.<\/p>\n\n\n\n

Agreement Details<\/strong>
Under the terms of the agreement, Alchemab will receive an undisclosed upfront payment and is eligible to receive discovery, development, and commercialization milestone payments, plus royalties. The collaboration involves the discovery, development, and commercialization of up to five novel therapies, leveraging Alchemab’s innovative technology and Eli Lilly’s expertise in drug development.<\/p>\n\n\n\n

Alchemab’s Technology and Goals<\/strong>
Alchemab has acquired hundreds of ALS samples and expects to identify antibodies associated with resilience in ALS patient samples using its proprietary technology. The company aims to advance the most promising candidates through the development pipeline, potentially offering new hope for patients suffering from ALS.<\/p>\n\n\n\n

Significance of the Partnership<\/strong>
This partnership between Alchemab Therapeutics and Eli Lilly & Co. highlights the commitment of both companies to advancing innovative treatments for ALS. By combining Alchemab’s cutting-edge technology with Eli Lilly’s resources and experience, the collaboration aims to bring novel therapies to market, improving patient outcomes and quality of life.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co….<\/p>\n","protected":false},"author":1,"featured_media":21184,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3114,199,911,24],"class_list":["post-21182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alchemab-therapeutics","tag-eli-lilly","tag-nyse-lly","tag-rare-orphan-disease-drugs"],"yoast_head":"\nAlchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21182\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments\" \/>\n<meta property=\"og:description\" content=\"UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21182\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T14:23:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-10T14:23:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments\",\"datePublished\":\"2025-01-10T14:23:03+00:00\",\"dateModified\":\"2025-01-10T14:23:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1017.png\",\"keywords\":[\"Alchemab Therapeutics\",\"Eli Lilly\",\"NYSE: LLY\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21182#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21182\",\"name\":\"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1017.png\",\"datePublished\":\"2025-01-10T14:23:03+00:00\",\"dateModified\":\"2025-01-10T14:23:07+00:00\",\"description\":\"UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21182\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1017.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1017.png\",\"width\":1080,\"height\":720,\"caption\":\"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21182#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments - Insight, China's Pharmaceutical Industry","description":"UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21182","og_locale":"en_US","og_type":"article","og_title":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments","og_description":"UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.","og_url":"https:\/\/flcube.com\/?p=21182","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-10T14:23:03+00:00","article_modified_time":"2025-01-10T14:23:07+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21182#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21182"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments","datePublished":"2025-01-10T14:23:03+00:00","dateModified":"2025-01-10T14:23:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21182"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png","keywords":["Alchemab Therapeutics","Eli Lilly","NYSE: LLY","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21182#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21182","url":"https:\/\/flcube.com\/?p=21182","name":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21182#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png","datePublished":"2025-01-10T14:23:03+00:00","dateModified":"2025-01-10T14:23:07+00:00","description":"UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21182#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21182"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21182#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png","width":1080,"height":720,"caption":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21182#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1017.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21182"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21182\/revisions"}],"predecessor-version":[{"id":21185,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21182\/revisions\/21185"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21184"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}